全文获取类型
收费全文 | 1575963篇 |
免费 | 116922篇 |
国内免费 | 3341篇 |
专业分类
耳鼻咽喉 | 19458篇 |
儿科学 | 52867篇 |
妇产科学 | 44011篇 |
基础医学 | 216582篇 |
口腔科学 | 39629篇 |
临床医学 | 138032篇 |
内科学 | 313520篇 |
皮肤病学 | 34248篇 |
神经病学 | 132426篇 |
特种医学 | 62345篇 |
外国民族医学 | 464篇 |
外科学 | 237785篇 |
综合类 | 35042篇 |
现状与发展 | 3篇 |
一般理论 | 489篇 |
预防医学 | 127116篇 |
眼科学 | 34137篇 |
药学 | 107630篇 |
1篇 | |
中国医学 | 4008篇 |
肿瘤学 | 96433篇 |
出版年
2021年 | 11028篇 |
2019年 | 11858篇 |
2018年 | 37118篇 |
2017年 | 28809篇 |
2016年 | 32476篇 |
2015年 | 17010篇 |
2014年 | 23527篇 |
2013年 | 34340篇 |
2012年 | 52300篇 |
2011年 | 67955篇 |
2010年 | 45810篇 |
2009年 | 37976篇 |
2008年 | 62725篇 |
2007年 | 67360篇 |
2006年 | 48228篇 |
2005年 | 48182篇 |
2004年 | 47247篇 |
2003年 | 46034篇 |
2002年 | 42783篇 |
2001年 | 73283篇 |
2000年 | 74960篇 |
1999年 | 61746篇 |
1998年 | 17215篇 |
1997年 | 15660篇 |
1996年 | 15678篇 |
1995年 | 14897篇 |
1994年 | 13507篇 |
1993年 | 12669篇 |
1992年 | 45888篇 |
1991年 | 43575篇 |
1990年 | 41618篇 |
1989年 | 39626篇 |
1988年 | 36244篇 |
1987年 | 35402篇 |
1986年 | 32893篇 |
1985年 | 31322篇 |
1984年 | 23859篇 |
1983年 | 20065篇 |
1982年 | 12255篇 |
1981年 | 10805篇 |
1979年 | 20711篇 |
1978年 | 14596篇 |
1977年 | 12100篇 |
1976年 | 11378篇 |
1975年 | 11634篇 |
1974年 | 14009篇 |
1973年 | 13538篇 |
1972年 | 12639篇 |
1971年 | 11473篇 |
1970年 | 10931篇 |
排序方式: 共有10000条查询结果,搜索用时 187 毫秒
121.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
122.
Psoriasis is a chronic, inflammatory, immune‐mediated disease. Approximately 30% of patients have disease onset before age 18 years. Psoriasis in children and adolescents may be difficult to control, with subsequent poor quality of life and psychosocial consequences. We describe the case of a 12‐year‐old boy with severe, refractory, chronic plaque psoriasis for 6 years. Various therapeutic regimens including different topical corticosteroids, topical vitamin D analogs, phototherapy, photochemotherapy, systemic therapy with methotrexate, cyclosporin, and combination therapies showed only partial or transient responses with frequent relapses. Because anti‐interleukin‐12/23 agents have been successfully used in adults with psoriasis, ustekinumab was initiated and our patient showed a rapid, excellent, sustained response. No recurrence or flares have been observed after 33 months of follow‐up. This case illustrates that ustekinumab may be an effective and safe therapeutic option in adolescents with psoriasis. 相似文献
123.
124.
David M. Presby Michael C. Rudolph Vanessa D. Sherk Matthew R. Jackman Rebecca M. Foright Kenneth L. Jones Julie A. Houck Ginger C. Johnson Janine A. Higgins P. Darrell Neufer Robert H. Eckel Paul S. MacLean 《Diabetes》2021,70(4):867
Moderate weight loss improves numerous risk factors for cardiometabolic disease; however, long-term weight loss maintenance (WLM) is often thwarted by metabolic adaptations that suppress energy expenditure and facilitate weight regain. Skeletal muscle has a prominent role in energy homeostasis; therefore, we investigated the effect of WLM and weight regain on skeletal muscle in rodents. In skeletal muscle of obesity-prone rats, WLM reduced fat oxidative capacity and downregulated genes involved in fat metabolism. Interestingly, even after weight was regained, genes involved in fat metabolism were also reduced. We then subjected mice with skeletal muscle lipoprotein lipase overexpression (mCK-hLPL), which augments fat metabolism, to WLM and weight regain and found that mCK-hLPL attenuates weight regain by potentiating energy expenditure. Irrespective of genotype, weight regain suppressed dietary fat oxidation and downregulated genes involved in fat metabolism in skeletal muscle. However, mCK-hLPL mice oxidized more fat throughout weight regain and had greater expression of genes involved in fat metabolism and lower expression of genes involved in carbohydrate metabolism during WLM and regain. In summary, these results suggest that skeletal muscle fat oxidation is reduced during WLM and regain, and therapies that improve skeletal muscle fat metabolism may attenuate rapid weight regain. 相似文献
125.
126.
ABSTRACTCommunication between health professionals and patients is an intergroup phenomenon where the health professional has the most power and status. Over the past few decades, there has been a steady increase in the availability to patients of information about healthcare and specific diseases on the Internet. In this paper, we ask whether the use of Internet health information assists patients to manage their consultations with health professionals better and whether it alters the intergroup dynamic by providing a more equal status for patients. In this study 370 participants from Australia and Canada completed a survey that included a ‘willingness to communicate with health professionals’ scale. They also commented on their use and trust of Internet health information. Thematic analysis suggests that patients’ use of Internet health information serves as a broker between patients and their health provider in health consultations. We discuss the implications of these findings for health practitioners as they address how easier Internet access influences patient interactions with health professionals. We consider future research directions these finding provide in explaining communication behaviour in this context. 相似文献
127.
J. Savige L. Amos Frank Ierino H. G. Mack R. C. Andrew Symons P. Hughes 《Ophthalmic genetics》2016,37(4):369-376
Background: Dense deposit disease and atypical hemolytic uremic syndrome are often caused by Complement Factor H (CFH) mutations. This study describes the retinal abnormalities in dense deposit disease and, for the first time, atypical haemolytic uremic syndrome. It also reviews our understanding of drusen pathogenesis and their relevance for glomerular disease. Methods: Six individuals with dense deposit disease and one with atypical haemolytic uremic syndrome were studied from 2 to 40 years after presentation. Five had renal transplants. All four who had genetic testing had CFH mutations. Individuals underwent ophthalmological review and retinal photography, and in some cases, optical coherence tomography, and further tests of retinal function. Results: All subjects with dense deposit disease had impaired night vision and retinal drusen or whitish-yellow deposits. Retinal atrophy, pigmentation, and hemorrhage were common. In late disease, peripheral vision was restricted, central vision was distorted, and there were scotoma from sub-retinal choroidal neovascular membranes and atypical serous retinopathy. Drusen were present but less prominent in the young person with atypical uremic syndrome due to a heterozygous CFH mutation. Conclusions: Drusen are common in forms of C3 glomerulopathy caused by compound heterozygous or heterozygous CFH mutations. They are useful diagnostically but also impair vision. Drusen have an identical composition to glomerular deposits. They are also identical to the drusen of age-related macular degeneration, and may respond to the same treatments. Individuals with a C3 glomerulopathy should be assessed ophthalmologically at diagnosis, and monitored regularly for vision-threatening complications. 相似文献
128.
A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases 下载免费PDF全文
129.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献
130.